ABBV vs SNY
AbbVie vs Sanofi — AI-powered side-by-side comparison
| Metric | ABBV | SNY |
|---|
| AI Score |
69
|
68
|
| Price |
$249.34
|
$43.70
|
| P/E Ratio |
70.28×
|
23.09×
|
| ROE |
-129.2%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
71.5%
|
72.8%
|
| Debt / Equity |
-11.93×
|
0.34×
|
| Dividend Yield |
2.7%
|
5.5%
|
| RSI (14) |
48.9
|
56.9
|
| Beta |
0.28
|
0.278
|
| Expected Upside |
—
|
+3.5%
|
AI Committee View
Current Innellis committee reasoning for ABBV versus SNY.
ABBV leads by 1 points.
ABBV scores 69/100 (Buy) versus SNY at 68/100 (Buy).
ABBV Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.20 across 84 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 5.4% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth